Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
ferroquine · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | - |
| 2 | ACTIVE_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| ferroquine (SSR97193) | DRUG | associated with artesunate |
| amodiaquine | DRUG | associated with artesunate |
Inclusion Criteria: * Body weight between 50 kg and 90 kg with Body Mass Index \>18 kg/m² * Presence of body temperature ≥ 37.5°C or history of fever within the last 24 hours * Monoinfection with Plasmodium falciparum and parasitemia within the 100 to 200,000/microL Exclusion Criteria: * Hypersen...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| GSK plc Sponsored ADR | GSK | 3 | PHASE3 | Tafenoquine, Primaquine, Chloroquine |
| Novartis AG Sponsored ADR | NVS | 1 | PHASE2 | INE963, KAE609, KLU156 |
| 60 Degrees Pharmaceuticals, Inc. | SXTP | 1 | PHASE2 | Tafenoquine |
Ferroquine is an investigational small molecule being developed for the treatment of malaria. It has been studied in African adult patients with uncomplicated malaria. The drug is currently in Phase 1 clinical development and is not yet approved by regulatory authorities.
Ferroquine is being developed by Sanofi, a pharmaceutical company listed on the stock exchange under the ticker symbol SNY. The company is conducting clinical research to evaluate the safety and activity of ferroquine in patients with malaria.
Ferroquine is currently in Phase 1 clinical development. It is an investigational drug, meaning it has not been approved for use outside of clinical trials. One Phase 1 study has been completed to assess its safety and activity in patients with uncomplicated malaria.
Ferroquine has been studied in one completed clinical trial with the identifier NCT00563914. This Phase 1 study compared ferroquine combined with artesunate versus amodiaquine combined with artesunate in African adult patients with uncomplicated malaria. The trial enrolled 72 male participants in Gabon and Kenya.
Ferroquine is a small molecule that acts as an antimalarial agent. It is being studied in combination with artesunate for the treatment of uncomplicated malaria. The drug is designed to target the malaria parasite, though its specific molecular target has not been disclosed.
No, ferroquine is not the same as amodiaquine. Ferroquine is a distinct investigational drug being developed by Sanofi. In clinical trials, ferroquine combined with artesunate was compared against amodiaquine combined with artesunate to evaluate their relative safety and activity in patients with malaria.